Blue Earth Therapeutics Expands Partnership with Seibersdorf Labor

Collaboration Now Includes Production of Therapeutic Agents

Blue Earth Therapeutics Ltd., a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies for cancer, today announced the expansion of its manufacturing collaboration with Seibersdorf Labor GmbH, a world-leading provider of isotope production and radiopharmaceutical services. The expanded partnership will include the production of Blue Earth's therapeutic agents, which are designed to target and destroy cancer cells.

Phase 1/2 Clinical Trial

The expansion of the partnership comes as Blue Earth's phase 1/2 clinical trial of its lead therapeutic candidate, 225Ac-rhPSMA-101, continues to progress. The trial is assessing the safety, tolerability, radiation dosimetry, and preliminary anti-tumor activity of the novel therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC).

Collaboration with Sinotau Pharmaceutical Group

In addition to the expanded partnership with Seibersdorf Labor, Blue Earth also recently announced a collaboration with Sinotau Pharmaceutical Group to bring the prostate cancer PET diagnostic imaging agent flotufolastat 18F to China. The diagnostic agent is designed to detect early-stage prostate cancer and inform treatment decisions.

These developments highlight Blue Earth's commitment to developing and delivering innovative therapies and diagnostics for cancer patients worldwide. The company's partnerships with leading organizations will enable it to accelerate the development and manufacturing of its therapeutic agents and provide valuable diagnostic tools to healthcare professionals.